Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced colorectal carcinoma.~* Progression on prior oxaliplatin-containing regimen used in 1st line setting for mCRC or progression within 6 months of end of oxaliplatin-containing regimen in the adjuvant setting.~* Tumor tissue available at time of screening for molecular profiling.~* Adequate performance status.~* Adequate glucose control, bone marrow, kidney, liver, and heart function.~Exclusion Criteria:~* Participation in other studies involving investigational drug(s) (Phases 1-4) before the current study begins and/or during study participation.~* Prior irinotecan treatment.~* Prior radiation to the pelvis or abdomen in the metastatic or locally advanced setting.~* History of Gilbert's syndrome.~* Active brain metastases.~* Deep vein thrombosis in the preceding 2 months.~* History of interstitial lung disease.~* RAS (KRAS/NRAS) wild type mCRC not previously treated with an anti-EGFR containing regimen (unless contraindicated or not considered standard practice per clinical site or country guidelines).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): PF-05212384 plus FOLFIRI
- Arm B (Type: ACTIVE_COMPARATOR): Bevacizumab plus FOLFIRI

Based on this trial design, predict the completion outcome and termination type (if applicable).